ArticleCureus2024
Androgen Deprivation Benefits in Low-Dose-Rate Brachytherapy With Hydrogel Spacer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aim to investigate the impact of rectal dose reduction of both androgen deprivation therapy (ADT) and concurrent hydrogel spacer placement (HSP) in patients treated with low-dose-rate (LDR) brachytherapy for prostate cancer and to determine whether there are variations in the degree of efficacy of dose reduction across different segments of the rectum.
methodsThis study involved 130 consecutive patients treated with I-125 LDR brachytherapy, with (ADT: n = 66) or without (nADT: n = 64) prior ADT, from June 2017 to April 2021. Among these, 13 ADT and 17 nADT patients underwent HSP following induction in May 2020, whereas the remaining patients (nHSP) included 53 ADT and 47 nADT individuals. In the post plan, a rectal dose assessment was made using the rectal volume (RV), divided by horizontal sections into three equal-length subparts (sRVs), such as high-, mid-, and low-RV. The mean sRV
resultsIn nADT patients, HSP significantly reduced the mean RV
conclusionThe combination of ADT and HSP for LDR prostate brachytherapy showed the potential to significantly reduce RV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.